Web conference to analyze latest trends, developments in the European melanoma skin cancer market

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

News and Articles
May 18 2010

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

In its upcoming web conference taking place on Tuesday, 25th May 2010, at 3 p.m. GMT Frost & Sullivan will focus on the European Melanoma Skin Cancer Market. Industry Analyst, Ranjith Gopinathan, will present an analysis of latest trends and developments in the market, competitive factors as well as challenges and strategic recommendations.

Highlights of the briefing include analyses of key current therapies, pipeline drugs and market dynamics in melanoma therapeutics.

To participate in this complimentary briefing, please email Katja Feick at [email protected] with your full contact details. Upon receipt of the above information, a registration link will be e-mailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

This briefing will benefit pharmaceutical companies, biotech companies, contract research organizations, investment banks, healthcare providers and hospitals by discussing current trends and providing forward projections for the European Melanoma Skin Cancer Market.

“Drugs currently available for advanced melanoma are not fully effective and have adverse effects. Consequently, the unmet needs of patients, especially those with advanced melanoma are quite high. The market therefore needs to focus on the current drugs in pipeline in order to stimulate market growth and a higher drug adoption in the future,” concludes Mr. Gopinathan.

Source:

Frost & Sullivan

Source: www.news-medical.net

Rate article
Add a comment